On the public citation graph

Antiviral Drug Discovery To Address the COVID-19 Pandemic

0 signed · 23 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1016/j.cell.2020.02.052openalex-snapshot

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

inferredcites →https://doi.org/10.1016/j.chom.2020.05.009openalex-snapshot

The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?

inferredcites →https://doi.org/10.1016/s0140-6736(20)31042-4openalex-snapshot

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

inferredcites →https://doi.org/10.1056/nejmoa2021436openalex-snapshot

Dexamethasone in Hospitalized Patients with Covid-19

inferredcites →https://doi.org/10.1073/pnas.83.6.1911openalex-snapshot

Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.

inferredcites →https://doi.org/10.1093/nass/nrl001openalex-snapshot

2′-Deoxy-4′-C-ethynyl-2-fluoroadenosine: A nucleoside reverse transcriptase inhibitor with highly potent activity against all HIV-1 strains, favorable toxic profiles and stability in plasma

inferredcites →https://doi.org/10.1101/2020.08.11.242834openalex-snapshot

AT-527 is a potent in vitro replication inhibitor of SARS-CoV-2, the virus responsible for the COVID-19 pandemic

inferredcites →https://doi.org/10.1126/science.abb4489openalex-snapshot

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

inferredcites →https://doi.org/10.1126/scitranslmed.abb5883openalex-snapshot

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

inferredcites →https://doi.org/10.1128/aac.01201-19openalex-snapshot

Safety, Pharmacokinetics, and Antiviral Activity of AT-527, a Novel Purine Nucleotide Prodrug, in Hepatitis C Virus-Infected Subjects with or without Cirrhosis

inferredcites →https://doi.org/10.1128/aac.47.10.3123-3129.2003openalex-snapshot

Novel bis -Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro

inferredcites →https://doi.org/10.1128/mbio.01833-20openalex-snapshot

GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.3710623openalex-extracted

inferred← citeshttps://doi.org/10.1016/j.antiviral.2026.106529openalex-snapshot

Application of emerging technologies in the antiviral field

inferred← citeshttps://doi.org/10.1016/j.ejmcr.2021.100013openalex-snapshot

Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment

inferred← citeshttps://doi.org/10.1101/2020.10.06.20208066openalex-snapshot

Real-World Effectiveness of Hydroxychloroquine, Azithromycin, and Ivermectin Among Hospitalized COVID-19 Patients: Results of a Target Trial Emulation Using Observational Data from a Nationwide Healthcare System in Peru

inferred← citeshttps://doi.org/10.1128/jvi.01551-21openalex-snapshot

Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters

inferred← citeshttps://doi.org/10.1186/s43141-021-00206-2openalex-snapshot

Anti-HIV reverse transcriptase plant polyphenolic natural products with in silico inhibitory properties on seven non-structural proteins vital in SARS-CoV-2 pathogenesis

inferred← citeshttps://doi.org/10.2478/abmj-2021-0005openalex-snapshot

Perspectives on Antiviral Drugs Development in the Treatment of COVID-19

inferred← citeshttps://doi.org/10.26434/chemrxiv.14125433openalex-snapshot

Repurposing Multi-Targeting Plant Natural Product Scaffolds In Silico Against SARS-CoV-2 Non-Structural Proteins Implicated in Viral Pathogenesis

inferred← citeshttps://doi.org/10.3390/ijms22115434openalex-snapshot

Existing Drugs Considered as Promising in COVID-19 Therapy

inferred← citeshttps://doi.org/10.3390/microorganisms9081731openalex-snapshot

The New Generation hDHODH Inhibitor MEDS433 Hinders the In Vitro Replication of SARS-CoV-2 and Other Human Coronaviruses

inferred← citeshttps://doi.org/10.5772/intechopen.111523openalex-snapshot

Drug Repurposing: Challenges and Successes in the Treatment of SARS-CoV-2

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.